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Abstract
Background: With increased access to genetic testing, variants of uncertain sig-
nificance (VUS) where pathogenicity is uncertain are being increasingly identified. 
More than 85% Osteogenesis Imperfecta (OI) patients have pathogenic variants in 
COL1A1/A2. However, when a VUS is identified, there are no pathways in place for 
determining significance.
Objective: Define a diagnostic pathway to confirm pathogenicity, providing patients 
with definitive genetic diagnosis, accurate recurrence risks, and prenatal testing 
options.
Methods: Functional studies on collagen secretion from cultured patient fibroblasts 
combined with detailed phenotyping and segregation family studies.
Results: We demonstrate data from a family with a VUS identified in type I collagen.
Family‐1: Six‐year‐old boy with failure‐to‐gain weight, talipes, fractures, on and off 
treatment with Pamidronate as diagnosis of OI uncertain. Transiliac bone biopsy at 2 
years of age demonstrated active new bone formation within periosteum; bone cortices 
were normal thickness but increased porosity. Trabecular bone showed features of ad-
vanced osteoporosis. Genetic testing identified a de novo COL1A1 c.206_208delTGT, 
p.Leu69del variant. Sibling with similar phenotype but no fractures as yet, tested posi-
tive for variant raising concerns regarding her diagnosis, and management.
Results from three independent experiments (cell immunofluorescence, collagen secre-
tion assay by Western Blot, and unbiased proteomics) from cultured patient fibroblasts 
demonstrate COL1A1 c.206_208delTGT, p.Leu69del variant causing a substantial de-
fect to collagen extracellular matrix assembly confirming variant pathogenicity.
Conclusion: Access to genetic testing in OI is increasing as advances in genetic 
technologies decreases cost; a clinical diagnostic pathway needs to be implemented 
for managing variants identified by such testing.
K E Y W O R D S
fractures, genetic analysis, osteogenesis imperfecta, targeted gene panel testing, Variant of uncertain 
significance
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1 |  INTRODUCTION
Inherited bone fragility disorders, of which Osteogenesis 
Imperfecta (OI) is the commonest, are rare (1 in 15,000) 
(Lim, Grafe, Alexander, & Lee, 2017). However, they are 
complex, require a multidisciplinary approach, consume 
significant resources, and often go unrecognized outside 
specialized settings, increasing patient burden. Bone fragil-
ity is commonly perceived as a disorder of the elderly, due 
to degenerative osteoporosis. However, recent advances in 
understanding of pathways relevant to treatment of osteopo-
rosis have come from studies of inherited bone fragility in 
multigenerational families. OI is used to describe inherited 
bone fragility disorders in childhood; mutations in 15 genes 
affecting type I collagen formation, processing and stabil-
ity, or osteoblast function have now been described. Over 
85% of patients with OI have pathogenic variants in type 1 
collagen genes (COL1A1/A2) (Forlino & Marini., 2016); the 
importance of type 1 collagen is underscored by the fact that 
collagen is the most abundant protein in the human body. 
Although, treatment is available for OI in the form of bis-
phosphonates, this does not improve the quality of bone or 
cure the condition.
Osteogenesis Imperfecta has historically remained a clin-
ical diagnosis in most cases due to costs and limited access 
to genetic testing. However, due to the need to provide pa-
tients and their families with accurate diagnosis, informa-
tion on prognosis, and reproductive options, genetic testing 
became increasingly part of their clinical work‐up. With re-
ducing costs of genetic testing and wider access to whole 
exome/ genome sequencing studies, more patients with 
mild‐moderate OI access genetic testing. Although, this is a 
positive development for families concerned, this does bring 
about unclassified variants, more frequently referred to as 
Variants of Uncertain Significance (VUS) where the signifi-
cance of a variant to assign causality is uncertain that needs 
interpreting.
In this study, we defined ways to clarify pathogenicity of 
a VUS leading to bone fragility using advanced sequencing 
technologies and to characterize the biological consequences 
of these mutations using advanced molecular cell biology. 
Patient samples were analyzed to define the extracellular ma-
trix (ECM) deposited by patient fibroblasts. We also defined 
the effect of a pathogenic variant (in procollagen encoding 
genes) on cell structure and function. Specifically, procolla-
gens present a problem to cells in terms of both the abundance 
and potentially because of their physical size (Malhotra & 
Erlmann, 2015). Adaptation of the canonical secretory path-
way machinery is thought to underpin effective procollagen 
secretion (Malhotra & Erlmann, 2015). We planned to define 
VUS in COL1A1 using a family encountered in clinical prac-
tice as an exemplar and determine how they affect trafficking 
of procollagen through the secretory pathway with a goal of 
defining mechanisms that might be targeted to modulate pro-
collagen secretion and ECM assembly.
There is increasing evidence that the composition of the 
ECM directly affects cell structure and function. We have 
recently found evidence for a potential feedback mechanism 
by which ECM controls the synthesis of nascent ECM gly-
coproteins (Stevenson et al., 2017). Here, we exploited the 
differences in patient cell‐derived matrix to determine how 
this affects further synthesis, secretion, and assembly or the 
glycoprotein‐rich ECM. This model suggested that cells have 
the capability to adapt to defective ECM and that further 
modulation of this capacity could be a worthwhile target for 
clinical intervention.
2 |  CLINICAL REPORT
2.1 | Family 1
The proband (Patient 1a) was the first child of healthy, non-
consanguineous White European parents with no significant 
family history. The pregnancy was complicated by hyperem-
esis but otherwise normal. Patient 1a was born at term with 
2.57 kg (0.4th–2nd centile) and was in a good condition im-
mediately after birth. He was noted to have bilateral cryp-
torchidism and under‐virilized male genitalia with a 46, XY 
karyotype. He required three surgeries in the first year of life 
for testicular descent. He was also noted to have bilateral cal-
caneus talipes equinovarus needing Ponseti correction. He 
developed fragility fractures, initially of his right femur, a 
transverse fracture at the top of the Ponseti above knee cast-
ing; then right proximal tibia with resultant nonunion and 
a fracture of the distal tibia identified incidentally. He was 
commenced on treatment with Pamidronate at 14 months of 
age which was discontinued briefly and recommenced until 
40 months of age.
Patient 1a is currently 7 years of age and presents with 
significant short stature (with height consistently just below 
the 0.4th centile, weight on the 0.4th centile and head circum-
ference between 0.4th–2nd centiles). He has normal motor 
development with mild speech delay and possible concerns 
regarding attention deficit hyperactivity disorder for which 
he is being assessed. On examination, he has pale skin with 
prominent veins over his forehead, brachycephaly, high ante-
rior hairline, blueish tinge to his sclerae, small pinched nose, 
small mouth with thin upper lip, and a small jaw. Figure 1 
shows evolution of his facial dysmorphism with age (aged 
7 months, 2 years, 3 years, and 4 years). He was also noted 
to have dental enamel hypoplasia and hypermobility of his 
small joints but no evidence of joint dislocation or herniation. 
He has not had any further fracture recently and currently, not 
on any treatment.
Investigations in Patient 1a have included a skeletal sur-
vey which demonstrated osteopenia with a small number 
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of Wormian bones in the lambdoid suture but with normal 
vertebrae (Figure 2). His bone biochemistry was reported 
normal and lumbar spine DXA showed bone mineral 
density (BMD) at the lower end of normal range. His bone 
densitometry at 7 years of age subsequently showed low 
forearm trabecular score with a background of normal 
F I G U R E  1  Facial dysmorphism in 
Patient 1a (aged 7 months, 2 years, 3 years, 
and 4 years) with small pinched nose, small 
mouth with thin upper lip, and prominent 
veins over forehead with brachycephaly, 
blueish tinge to sclerae, and dental enamel 
hypoplasia
Paent 1 a 
aged,
7 months
2 years
3 years
4 years
F I G U R E  2  (a) Skeletal survey 
demonstrating osteopenia with Wormian 
bones, normal vertebrae in Patient 1a with 
evidence of fractured femur in comparison 
to (b) X‐rays in Patient 1b who has no 
evidence of OI part from osteopenia
(a)
(b)
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bone profile (pQTC score −2.24 SDS with a cortical and 
trabecular score of −1.58SDS) and a delayed bone age by 
1.5 years. His array CGH showed a 619 Kb maternally in-
herited Xp22.3 duplication which was predicted to be non-
pathogenic. His ophthalmology review and cranial USS 
were normal.
A transiliac bone biopsy performed at 2 years of age 
demonstrated active new bone formation within the peri-
osteum; bone cortices were of normal thickness but of in-
creased porosity. The trabecular bone showed features in 
keeping with advanced osteoporosis. Overall, the cortical 
osteopenia noted was deemed to be a consequence of in-
creased osteoclastic to osteoblastic activity within the tra-
becular bone presumed to be due to severe osteoporosis 
(Figure 3). Genetic analysis for COL1A1/A2 identified a de 
novo novel in‐frame deletion in exon 2 which is described 
in further detail below.
The younger sister of this patient (Patient 1b) was as-
sessed in clinic and found to have similar facial dysmorphism 
as the brother and tested positive for the same familial vari-
ant indicating gonadal mosaicism in one of the parents. She 
was born following a normal pregnancy at 37 weeks gestation 
with a birth weight of 2.40 kg (0.4th centile) and was in a 
good condition immediately after birth. On examination at 9 
months of age, she was noted to have similar facial appear-
ance to her brother (Figure 4 showing younger sibling aged 
10 months with Patient 1a aged 6 years) with blueish sclerae 
and premature thelarche (with normal endocrine investiga-
tions). Her growth parameters were all on the ninth centile. 
She has not sustained any fractures so far and her skeletal sur-
vey was reported normal. She remains under follow‐up with 
the Metabolic Bone team.
In view of Patient 1a clinical phenotype, fracture history, 
bone biopsy findings, and use of Pamidronate for treatment 
of his initial bone fragility, he was presumed to have a clinical 
diagnosis of type 1 OI. His sister was thought to have osteo-
penia without any fractures which may partly attributable to 
her younger age and closer monitoring of her bone health.
3 |  MATERIALS AND METHODS
3.1 | Genetic analysis
Targeted gene testing for COL1A1/A2 was performed using 
previously published methods in Family 1.
F I G U R E  3  Bone biopsy undertaken 
at 2 years of age in Patient 1a demonstrating 
active new bone formation within the 
periosteum and increased osteoclasis 
within the cortex confirming advanced 
osteoporosis. Trabecular bone showed 
cortical osteopenia as a consequence 
of relative increase in osteoclastic over 
osteoblastic activity. The findings from bone 
biopsy were reported to be very typical of 
severe osteoporosis/ osteogenesis imperfecta 
with evidence of compensatory periosteal 
new bone formation to thicken the cortex 
but the new cortical bone deposited on 
the endosteal surface was also found to be 
significantly osteoporotic
Biopsy consists of corcal and 
a lile subcorcal boneBiopsy shows normal lamellar bone in 
the cortex and grossly abnormal 
distribuon of collagen in the the very 
thick periosteal new bone
Toluidine blue
Toluidine blue
viewed in 
polarised light
Massons trichrome
Very thick acvated 
cambial layer of 
periosteum and osteoid 
on interface between 
periosteum and bone 
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3.2 | Ethical compliance
This study was performed with appropriate written consent 
from the family and as part of a research study approved by 
an ethics committee.
3.3 | Cell culture and immunofluorescence
Primary control and patient‐derived fibroblasts (Patient 1 
a) were cultured in Ham’s F10 (Life Technologies, Paisley, 
UK) supplemented with 12% fetal calf serum.
To investigate intracellular procollagen transport in con-
trol and patient cells, cells were grown for 48–72 hr on glass 
coverslips and incubated in the presence of 167 µM (50 µg/
ml) ascorbic acid for 30  min prior to fixation. Cells were 
fixed with 4% paraformaldehyde in PBS and processed for 
immunofluorescence using either only anti‐collagen IαI 
(Novus Biologicals NB600‐408, rabbit, 1:2,000) for analysis 
of the extracellular collagen, or anti‐collagen IαI in combi-
nation with the COPII marker anti‐Sec31A (BD Biosciences 
612,350, mouse, 1:1,000) or the cis‐Golgi marker anti‐
GM130 (BD Biosciences 610,823, mouse, 1:1,000) and 
imaged by confocal microscopy as described previously 
(McCaughey et al., 2016) using an Alexa‐Fluor‐anti‐rab-
bit‐568‐conjugated (Thermo Fisher Scientific) and/or Alexa‐
Fluor‐anti‐mouse‐488‐conjugated secondary antibody, 
Prolong Diamond with DAPI for mounting and a Leica SP5 
for analysis and image acquisition.
Osteoclasc resorpon
Osteoclasts
Tunneling resorpon 
from normal corcal 
bone into abnormal 
periosteal bone
Very eroded subcorcal bone
Osteoid of normal 
thickness but all covered in 
osteoblasts
F I G U R E  3  Continued
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3.4 | Collagen secretion assay by 
Western Blot
For semiquantitative analysis of COL1a1 levels in con-
trol and patient cells, cells were seeded confluent into a 
6  cm dish and grown for 24  hr, following incubation in 
serum‐free media either without or supplemented with 
167  µM (50  µg/ml) ascorbate for 24  hr at 37°C and 5% 
CO2. The medium was collected and the cells incubated in 
lysis buffer containing 50  mM Tris‐HCl, 150  mM NaCl, 
1% (v/v) triton‐X‐100, 1% (v/v) protease inhibitor cocktail 
(Calbiochem) at pH 7.4 for 15 min on ice. Protein fractions 
of medium and lysate were centrifuged at 13,500  rpm at 
4°C for 10 min. The cell pellet was discarded. The superna-
tant was denatured and run under reducing conditions on a 
3%–8% Tris‐Acetate precast gels (NuPAGE ®) for 75 min 
at 150 V in Tris‐Acetate running buffer supplemented with 
antioxidant. Transfer of protein bands onto a nitrocel-
lulose membrane was performed at 300 mA for 106 min. 
The membrane was blocked using 5% (w/v) milk powder 
in TBST overnight at 4°C and incubated with antibod-
ies against collagen IαI (Novus Biologicals NB600‐408; 
rabbit, 1:1,000) and DIC74.1 (Merck MAB1618, mouse, 
1:1,000) as loading control for 1.5 hr at RT. After repeated 
rinsing with TBST, the membrane was incubated for 1.5 hr 
at RT with HRP‐conjugated antibodies diluted in the 
blocking solution (1:5,000) against mouse and rabbit, re-
spectively. The wash step was repeated, and detection was 
performed using Promega WB‐ECL reaction reagents and 
autoradiography films with overnight exposure and subse-
quent development.
3.5 | Cell extraction and harvest of cell 
derived matrix
Cells were rinsed twice with PBS prior to incubation with 
20 mM ammonium hydroxide in PBS for 5 min at room tem-
perature and vigorous shaking on a rocker. Detached cells were 
rinsed via three washes with ddH2O. Plates containing the cell‐
derived matrix were incubated with DNAseI at 10 µg ∙ ml‐1 for 
30 min at 37°C followed by three washes with ddH2O. Matrix 
proteins were covered with 5% acetic acid and incubated 
at 4°C overnight. Matrix proteins were extracted with a cell 
scraper from the dish after addition of matrix buffer containing 
125 mM Tris‐HCl, pH 6.8, 0.1% SDS, 10% glycerol, 1% DDT 
and a protease inhibitor cocktail (Calbiochem). Protein extracts 
and acetic acid fractions were combined into a polypropylene 
ultracentrifugation tube and five volumes of prechilled acetone 
(−20°C) were added to the samples and proteins were precipi-
tated overnight at −20°C. Proteins were pelleted via a Sorvall 
Evolution centrifuge at 15,000 × g for 10 min at 4°C. The su-
pernatant was decanted and the protein pellet air‐dried at room 
temperature. Samples were resuspended in matrix buffer and 
the protein concentration was determined using NanoDrop at 
280 nm. Samples for subsequent proteomics analysis contained 
100 µg of protein extract at 1–2 µg/µl.
3.6 | Proteomic analysis
For TMT Labeling and high pH reversed‐phase chromatog-
raphy, the samples were labeled with tandem mass tag (TMT) 
multiplex reagents according to the manufacturer’s protocol 
(Thermo Fisher Scientific, Loughborough, UK) and the la-
beled samples were pooled. The pooled sample was then 
desalted using a SepPak cartridge according to the manufac-
turer’s instructions (Waters, Milford, Massachusetts, USA). 
Eluate from the SepPak cartridge was evaporated to dryness 
and resuspended in buffer A (20 mM ammonium hydrox-
ide, pH 10) prior to fractionation by high pH reversed‐phase 
chromatography using an Ultimate 3,000 liquid chromatog-
raphy system (Thermo Fisher Scientific). In brief, the sam-
ple was loaded onto an XBridge BEH C18 Column (130 Å, 
3.5 µm, 2.1 mm × 150 mm, Waters, UK) in buffer A and 
peptides eluted with an increasing gradient of buffer B 
(20 mM ammonium hydroxide in acetonitrile, pH 10) from 
0% to 95% over 60 min. The resulting fractions were evapo-
rated to dryness and resuspended in 1% formic acid prior 
to analysis by nano‐LC MSMS using an Orbitrap Fusion 
Tribrid mass spectrometer (Thermo Fisher Scientific).
3.7 | Semiquantification of extracellular 
collagen levels
In order to estimate the relative amount of secreted col-
lagen type I, the corrected total cell fluorescence (CTCF) 
F I G U R E  4  Younger sibling aged 9 months in Family 1 
demonstrating strikingly similar facial dysmorphism to older brother 
aged 6 years
Paent 1 b 
aged,
10 months
with older 
sibling aged 6 
years
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per field of view of four to five randomly picked areas per 
sample (control and patient cells) was calculated accord-
ing to (McCloy et al., 2014) where CTCF  =  [integrated 
density  −  (area of selected cell  ×  mean background fluo-
rescence)]. Subsequently, the ratio of the patient sample 
CTCFs and the mean of the control sample CTCFs were cal-
culated. The resulting ratios originate from three independ-
ent experiments.
3.8 | Nano‐LC mass spectrometry
High pH RP fractions were further fractionated using an 
Ultimate 3,000 nano‐LC system in line with an Orbitrap 
Fusion Tribrid mass spectrometer (Thermo Fisher 
Scientific). In brief, peptides in 1% (vol/vol) formic acid 
were injected onto an Acclaim PepMap C18 nano‐trap col-
umn (Thermo Fisher Scientific). After washing with 0.5% 
(vol/vol) acetonitrile 0.1% (vol/vol) formic acid, peptides 
were resolved on a 250 mm × 75 μm Acclaim PepMap C18 
reverse phase analytical column (Thermo Fisher Scientific) 
over a 150 min organic gradient, using seven gradient seg-
ments (1%–6% solvent B over 1  min, 6%–15% B over 
58 min, 15%–32% B over 58 min, 32%–40% B over 5 min, 
40%–90% B over 1 min, held at 90% B for 6 min and then 
reduced to 1% B over 1 min) with a flow rate of 300 nl/min. 
Solvent A was 0.1% formic acid and Solvent B was aque-
ous 80% acetonitrile in 0.1% formic acid. Peptides were 
ionized by nano‐electrospray ionization at 2.0 kV using a 
stainless steel emitter with an internal diameter of 30 μm 
(Thermo Fisher Scientific) and a capillary temperature of 
275°C.
All spectra were acquired using an Orbitrap Fusion 
Tribrid mass spectrometer controlled by Xcalibur 2.0 soft-
ware (Thermo Fisher Scientific) and operated in data‐depen-
dent acquisition mode using an SPS‐MS3 workflow. FTMS1 
spectra were collected at a resolution of 120,000, with an 
automatic gain control (AGC) target of 400,000 and a max 
injection time of 100  ms. Precursors were filtered with an 
intensity range from 5,000 to 1E20, according to charge 
state (to include charge states 2–6) and with monoisotopic 
precursor selection. Previously interrogated precursors were 
excluded using a dynamic window (60 s ± 10 ppm). The MS2 
precursors were isolated with a quadrupole mass filter set to 
a width of 1.2  m/z. ITMS2 spectra were collected with an 
AGC target of 10,000, max injection time of 70 ms and CID 
collision energy of 35%.
For FTMS3 analysis, the Orbitrap was operated at 30,000 
resolution with an AGC target of 50,000 and a max injec-
tion time of 105 ms. Precursors were fragmented by high en-
ergy collision dissociation (HCD) at a normalized collision 
energy of 55% to ensure maximal TMT reporter ion yield. 
Synchronous Precursor Selection (SPS) was enabled to in-
clude up to 5 MS2 fragment ions in the FTMS3 scan.
3.9 | Data analysis
The raw data files were processed and quantified using 
Proteome Discoverer software v2.1 (Thermo Fisher 
Scientific) and searched against the UniProt Human database 
(140,000 entries) using the SEQUEST algorithm. Peptide 
precursor mass tolerance was set at 10 ppm, and MS/MS tol-
erance was set at 0.6 Da. Search criteria included oxidation 
of methionine and proline (+15.9949) as a variable modi-
fication and carbamidomethylation of cysteine (+57.0214) 
and the addition of the TMT mass tag (+229.163) to pep-
tide N‐termini and lysine as fixed modifications. Searches 
were performed with full tryptic digestion and a maximum 
of three missed cleavage sites was allowed. The reverse data-
base search option was enabled and the data were filtered to 
satisfy false discovery rate (FDR) of 5%.
4 |  RESULTS
4.1 | Family 1
4.1.1 | Genetic analysis
Targeted testing for COL1A1/A2 identified a de novo 
COL1A1 c.206_208delTGT, p.Leu69del variant which re-
sults in deletion of one amino acid residue on the N‐propep-
tide of proα1(1) chain of type 1 collagen. This variant has 
not been reported in the OI variant database. Triple helix in‐
frame deletions of COL1A1 have been reported previously 
but are not common, and typically result in a more severe 
phenotype. This variant remained a VUS until further func-
tional studies were undertaken to prove pathogenicity.
4.1.2 | Collagen processing and proteomics
Figure 5 demonstrates experimental result from fibroblasts 
in Patient 1a. Results from three different experiments dem-
onstrate the COL1A1 c.206_208delTGT, p.Leu69del variant 
causing a substantial defect to collagen extracellular matrix 
assembly.
Figure 5a shows that localization of intracellular COL1A1 
in patient cells was normal compared to control samples. In 
the presence of ascorbate COL1A1 localizes to the endoplas-
mic reticulum and in higher concentration to areas of the Golgi 
apparatus. Similarly, the morphology of COL1A1 in the extra-
cellular matrix of patient cells is similar compared to control 
cells, aside from patches of high abundance in patient samples. 
The overall abundance of COL1A1 appears to be lower in the 
patient sample by immunofluorescence (Figure 5B). This result 
is further supported by the protein levels detected by immuno-
blotting (Figure 5C), showing lower COL1A1 levels compared 
to control samples. Furthermore, lysates of patient‐derived cells 
and medium from these cells do not contain increased COL1A1 
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following addition of ascorbate, as seen for the control sam-
ple. Proteomics data revealed a consistent decrease in COL1A1, 
COL1A2, COL3A1, and COL5A2 in the cell‐derived extracellu-
lar matrix of patient cells compared to the controls. Collagens 
3 and 5 are both interactors with collagen type I in the extra-
cellular matrix. The interdependence of collagen isotypes has 
been described previously. It is known that dermal collagen 
fibrils contain both type I and type III collagens (Fleischmajer, 
MacDonald, Perlish, Burgeson, & Fisher, 1990) and that type 
I and type V collagens can also be found in the same fibrils 
(Birk, Fitch, Babiarz, & Linsenmayer, 1988). Expression of 
procollagens I and III can also be coregulated, for example, by 
glucocorticoid signaling (Walsh, LeLeiko, & Sterling, 1987). 
This is consistent with our findings in which the secretion and 
assembly of multiple collagen isotypes is reduced.
5 |  DISCUSSION
In Clinical Genetics practice, we currently undertake diag-
nostic genetic testing for a whole host of genetic conditions to 
confirm diagnosis, clarify prognosis, inform recurrence risks, 
F I G U R E  5  Collagen secretion defects in fibroblasts from patient 1a. (a) Control or patient fibroblasts incubated for 30 min to promote 
procollagen secretion were immunolabeled to detect COL1A1 (red) and in green, either Sec31A (to mark COPII‐coated ER exit sites) or GM130 
(to mark the Golgi apparatus). (b) Extracellular collagen matrix was labeled to detect COL1A1. (c) Quantification of the mean Corrected 
Total Cell Fluorescence (CTCF) for COL1A1. Points show mean intensity from three independent experiments. Bars show standard deviation. 
(d) Immunoblot for COL1A1 in media (M) or lysates (L) of control or patient fibroblasts incubated in the presence of absence of ascorbate. 
(e) Unbiased proteomics was used to measure extracellular matrix collagens secreted from control or patient fibroblasts. Results from three 
independent experiments are shown. A ratio <1 indicates reduced collagen secretion from patient cells
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and provide options for prenatal genetic testing. However, 
with increased access to genetic testing, we are identifying 
variants of unclassified significance, also referred to as VUS 
where the pathogenicity of the variant is not certain. This is 
becoming more of an issue with increased access to next‐gen-
eration sequencing technologies and testing of more patients 
with a given genetic condition. Currently, when we identify 
an unclassified variant from genetic testing, apart from seg-
regation studies to identify if the variant tracks with the phe-
notype in the family and awaiting further knowledge, there is 
nothing further we can offer in the routine diagnostic setting. 
This affects decisions regarding treatment, unable to clarify 
diagnosis or provide informed recurrence risks; hence, there 
is a clear unmet need.
In our center, we see a large cohort of patients with OI 
and undertake targeted genetic analyses in this group. Based 
on further research into collagen processing and extracellular 
matrix assembly of collagen, we plan to develop a diagnos-
tic pathway to better identify and clarify the pathogenicity of 
these variants in order to provide patients with a more defini-
tive genetic diagnosis, accurate recurrence risks, and options 
of prenatal testing.
Data presented here show that with a VUS in COL1A1, 
we have been able to clarify pathogenicity by undertaking de-
tailed phenotyping of extended family; segregation studies in 
family members (affected vs. unaffected) and functional stud-
ies on cultured fibroblasts. With projects underway nationally 
including the 100,000 Genomes Project (https ://www.genom 
icsen gland.co.uk/); VUS will become more of an issue with 
increased access to genetic testing.
Using one such family with COL1A1 VUS shown here, 
we are able to confirm that this variant is pathogenic. The 
reduction in secretion and assembly of type 1 collagen is 
consistent with a mild OI presentation in Patient 1a. We 
have used light microscopy to visualize the structure of the 
extracellular matrix and intracellular collagen. We used 
TMT to label individual samples with isobaric tags and 
quantify abundance of key proteins by LC‐MS/MS. Patient 
1a has a more severe phenotype compared to his sibling 
which may simply reflect the fact that she is younger and 
been more closely monitored clinically although, it is also 
possible that there are genetic modifiers which is altering 
the clinical severity in these siblings. Phenotypic variabil-
ity even within the same family is a well‐recognized feature 
in OI and studies are ongoing to evaluate why this may be 
the case in large multi‐generational families with the same 
genotype but variable severity.
Cells from Patient 1a deposit fewer collagen fibrils that 
often form more densely packed areas. These data show that 
pathogenic variant in procollagen lead to defects in the assem-
bly and deposition, not only of collagen but of many other ECM 
proteins. Data presented here shows that detailed phenotyping 
in addition to segregation studies and cell studies focussing 
on light microscopy, quantitative proteomics, and analysis of 
procollagen trafficking and secretory pathway function in the 
workflow can help clarify the pathogenicity of such variants.
Our analysis of fibroblasts from Patient 1a with a VUS in 
COL1A1 also provides mechanistic insight into key questions 
of fundamental cell biology. Our recent work has led us to 
hypothesize that the composition of the ECM dictates the or-
ganization and function of the secretory pathway by feedback 
control. Our hypothesis is that these are linked directly such 
that not only does secretion directly impact the composition 
of the ECM but equally the composition of the ECM dictates 
the composition of the Golgi via a feedback mechanism.
For OI families, this opens the option of testing of un-
affected family members to clarify risk, prenatal genetic 
testing, follow‐up arrangements for the unaffected relatives, 
thus having a positive impact for the families as demonstrated 
clearly in the family reported here.
6 |  CONCLUSIONS
With advances in genetic testing and access to whole exome/ 
genome sequencing technologies, VUS are an increasing 
finding in Clinical Genetics practice. This is particularly 
relevant for OI where there are treatment options available 
and management decisions are made on the basis of genetic 
testing results in conjunction with clinical and radiological 
evidence. This is also true in nonaccidental injury scenario 
where access to genetic testing is increasing in order to as-
certain/ refute diagnosis of OI. Having a clinical pathway 
for clarifying diagnosis of such VUS identified in type 1 
Collagen genes in OI which goes beyond the realms of seg-
regation studies and detailed phenotyping is extremely useful 
in this patient group. Studies such as this will aid in under-
standing more about underlying disease mechanism and pro-
vide insights into collagen secretion advancing us further in 
translating these discoveries into patient benefit.
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